Epitalon dosage and evidence

What is Epitalon?

How does Epitalon work?

The idea is that Epitalon works as a signal that turns genes on or off, not by fitting a receptor. In people, the most repeated finding is about melatonin, the sleep hormone. A course of the parent pineal extract raised night-time melatonin in older people whose levels were low. It tended to lower it in people whose levels were normal. In human fetal skin cells in a dish that had no telomerase, Epitalon switched on the telomerase gene. The enzyme became active and the telomeres got longer. Untreated cells stopped dividing at round 34. Treated cells kept going to round 44, about ten extra rounds of division. A 2025 study from an unrelated lab found the same direction of effect in normal human cells: longer telomeres, more so at higher doses. Cancer cells in that study used a different route. The step that would link the two ideas is a tiny peptide getting into the cell's nucleus and acting on DNA directly. Only the group that made it has reported that, and it is not settled.

What have studies in people found about Epitalon?

There is human data on Epitalon and its parent pineal extract, Epithalamin, going back decades. The biggest studies counted deaths, which is a very ambitious thing to measure for a compound this early. Every human study comes from one research group: Vladimir Khavinson's institute in St Petersburg and its long-time partners at the Institute of Gerontology in Kiev.

• 266 older people in Russia and Ukraine were followed for 6 to 8 years. They got the peptide extracts only in the first 2 to 3 years. Deaths were 1.6 to 1.8 times lower on Epithalamin, 2.0 to 2.1 times lower on Thymalin, and 2.5 times lower on both. A smaller group that took both every year for 6 years had 4.1 times fewer deaths than the untreated group. Colds and chest infections fell 2.0 to 2.4 times. Khavinson and Morozov, Neuro Endocrinology Letters, 2003.
• 39 older heart patients got 6 courses of Epithalamin over 3 years plus their usual treatment. 40 patients got usual treatment only. This was at the Institute of Gerontology in Kiev. At 12 years, 28% fewer treated patients had died, and half as many had died of heart disease. Heart failure and chest infections were also about half as common. The 15-year report on the same patients added slower ageing of the heart and blood vessels, better stamina and a normal melatonin rhythm. Korkushko and colleagues, 2006 and 2011.
• Melatonin in healthy older people: a course of Epithalamin raised night-time melatonin in those whose levels were low. It tended to lower it in those whose levels were normal. The authors read this as bringing levels back to normal, not just pushing them up. The abstract does not say how many people were in each group. Korkushko and colleagues, 2004.
• 55 older people with low pineal output got a 100 mg course of Pineamin, a related pineal extract. Their night-time melatonin marker in urine was 1.9 times their own level before treatment. Everyone got the drug. There was no untreated group to compare against. Trofimova and colleagues, Advances in Gerontology, 2017.
• Retinitis pigmentosa, an eye disease that slowly destroys the retina: Epitalon was reported to help in 90% of patients. The paper does not say how many patients there were, how they were picked, or what counted as helping. So the 90% figure cannot be read. Khavinson and colleagues, Neuro Endocrinology Letters, 2002.
• This one is human cells in a dish, not people, but it is the finding Epitalon is famous for. In human fetal skin cells with no telomerase, Epitalon switched telomerase on and made telomeres longer (2003). Treated cells kept dividing to round 44, against round 34 for untreated cells (2004). In 2025, a group at Brunel University London with no link to the original group found longer telomeres in normal human cells, more so at higher doses.
• No study of Epitalon, Epithalon, Epithalamin or AEDG is registered on ClinicalTrials.gov as of September 2026.

What this does not tell you: That it truly slows ageing. In none of these studies did people get a hidden dummy treatment. None set out in advance what it would measure or how. The two long studies on deaths used Epithalamin, the cow pineal extract. They did not use the lab-made peptide sold today as Epitalon, so they do not test what people buy. The published summaries often leave out group sizes, how people were assigned to groups, and how sure the numbers are. Most of the work came out in Russian journals whose review process a Western reader cannot check. Every human study above comes from one institute and its long-time partners. The results fit a real effect. They fit just as well with patients and doctors who expected a good result and got one. Nothing published so far tells the two apart.

What do people who took Epitalon report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Most people use short bursts, not daily use. A common plan is 5 to 10 mg a day for 10 to 20 days, two or three times a year. That copies the course plan in the Russian studies. People say switching telomerase on is a one-time event, so daily use is not needed. That reason comes from the proposed mechanism. It has never been tested in a human dosing study.
• Sleep comes up more than anything. SelfAssay collected 258 first-hand reports from 236 people. Better sleep came up 95 times, far ahead of anything else. Longevity and longer telomeres came up 23 times each, but as hopes, not as things people felt. Vivid dreams and steadier wake-up times were also common.
• The complaints in that same set are about the same things, not the whole body: trouble sleeping 6, insomnia 5, sleepiness 3, anxiety 3, waking too early 2, low mood 1. People who react badly tend to react in sleep and mood.
• Many users say they felt nothing at all. Long-running longevity forum threads keep asking the same question for years without an answer. Has anyone gotten a result they could measure? And what would a longer telomere even feel like?
• The telomere and biological-age numbers people post are the weakest part. One person's months-long self-test used a saliva DNA test of biological age, not a telomere test at all. The only telomere test they could find cost about 290 dollars and needed a blood draw and a doctor. Others in the thread argued the biological-age result was not believable. Home telomere and biological-age tests are so rough that their error covers the whole claimed effect. Almost none of these reports include a starting test on the same kit.
• People complain a lot about price and sourcing. In August 2026, a price tracker listed 93 offers from 73 sellers, from 1.14 to 26 US dollars per milligram. The average was 4.11. Vials ran from 17 to 160 dollars. A more than twentyfold price gap for the same four amino acids shows the purity problem. A peptide this short is cheap to make, easy to under-fill and impossible to check by eye.
• Side effect reports are mild, rare and vague. At least one forum user described a lot of swelling in the face. No safety database stands behind any of this. Long-term safety in people has never been studied outside the Russian studies.

Sources: LongeCity 'Telomeres' forum threads on Epitalon and Epithalon; the Age Reversal Forum self-experimentation thread on Epitalon (AEDG); SelfAssay's aggregated community corpus for Epitalon (258 reports, 236 contributors); vendor price tracking at peppers.market (73 vendors, retrieved August 2026). Reddit's r/Peptides is the most cited venue for this compound but was not directly readable when this section was compiled, so nothing here is drawn from it.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2003
  Peptides of pineal gland and thymus prolong human life

  This is the study the life extension claim rests on, and it is not built to carry it. 266 older people in Russia and Ukraine were followed for six to eight years, dosed only in the first two or three. Deaths were reported lower in every treated group, from about a third fewer up to four times fewer in one small subgroup dosed every year. Chest and airway infections were reported at roughly half the usual rate. Everybody knew who got what, and every figure comes from one group.

  266 elderly people in Russia and Ukraine followed 6 to 8 years, treated during the first 2 to 3 years: mortality 1.6 to 1.8-fold lower with Epithalamin, 2.0 to 2.1-fold lower with Thymalin, 2.5-fold lower with both, and 4.1-fold lower in a subgroup given both annually for 6 years; acute respiratory illness fell 2.0 to 2.4-fold. Open-label, single research lineage.

  PMID 14523363 Neuro Endocrinology Letters
• Study in people2006
  Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging

  A long Russian study reported fewer deaths, and nobody was kept in the dark. Older heart patients showing signs of fast ageing were followed for twelve years. Some got courses of epithalamine on top of usual treatment, the rest had usual treatment only. Deaths from any cause were reported 28% lower, and deaths from heart disease half as common. They scored younger on a measure of functional age and could exercise for longer. There was no dummy treatment, so belief and extra attention cannot be ruled out.

  12-year randomized study in elderly coronary patients with accelerated cardiovascular aging: total deaths 28% lower and cardiovascular mortality 2-fold lower than control on the same basic therapy, with lower functional age and higher exercise tolerance. Not blinded, not placebo-controlled.

  PMID 17426848 Bulletin of Experimental Biology and Medicine
• Study in people2011
  Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up

  The same small group of Kiev heart patients, followed for much longer. 39 heart patients took six courses of epithalamin over three years alongside their usual treatment. 40 others had usual treatment only. The treated group was reported to age more slowly in the heart and blood vessels, keep more stamina, recover a normal melatonin rhythm and die less often. Seventy-nine people is a very small base for a claim about dying. The title says pituitary gland; the preparation studied is the pineal one.

  The same Kiev cohort at 15 years: 39 coronary patients given 6 courses of Epithalamin over 3 years plus basic therapy versus 40 on basic therapy alone, reporting slower cardiovascular aging, preserved physical endurance, normalized melatonin rhythm and significantly lower mortality. The title says pituitary; the text is about the pineal preparation Epithalamin.

  PMID 22451889 Bulletin of Experimental Biology and Medicine
• Study in people2004
  Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people

  A course of the drug pushed night-time melatonin back up in older people who were short of it. In people whose melatonin was already normal, it tended to nudge the level down instead. The database records it as a trial where chance decided who got what. The abstract never says how many people were in each group. Without that, nobody can judge how solid the result is. It also measures a hormone in the blood, not how anyone slept or felt.

  Indexed as a randomized controlled trial. A course of Epithalamin raised night-time plasma melatonin in elderly subjects whose pineal activity was initially low and tended to lower it in those with normal function. Group sizes are not given in the abstract.

  PMID 15452611 Bulletin of Experimental Biology and Medicine
• Study in people2017
  Pineamin increased pineal melatonin synthesis in elderly people

  Melatonin output went up, and there was nobody to compare it against. 55 older patients with low night-time melatonin took a course of Pineamin, a related pineal preparation rather than Epitalon itself. Their overnight melatonin breakdown product measured nearly twice their own level before treatment. Everybody in the study got the drug. With no untreated group there is no way to know what would have happened anyway. And it measures a marker in urine, not sleep, not health, not ageing.

  55 elderly patients with reduced pineal melatonin output given a 100 mg course of Pineamin, a related pineal polypeptide complex, had night urinary 6-sulfatoxymelatonin 1.9-fold above their own pre-treatment level. Single-arm before-and-after with no control group.

  This study gave people Pineamin (a pineal polypeptide complex, not epitalon), not Epitalon. It is here because it belongs on the record, and it is excluded from every count on this page.

  PMID 28849889 Advances in Gerontology
• Study in people2002
  Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa

  This one should not be counted as evidence at all. The paper reports a positive effect in 90% of patients treated for degenerating retinas, alongside preserved retinal structure in rats. It never says how many patients there were. It never says how they were chosen. It never says what counted as a positive effect. A percentage with no group size and no definition cannot be checked by anyone. Treat it as a claim, not a finding.

  Reports a positive clinical effect in 90% of patients treated for degenerative retinal lesions, alongside preserved retinal structure and bioelectric activity in Campbell rats. The paper does not state how many patients were treated, how they were selected, or how a positive effect was defined.

  PMID 12195242 Neuro Endocrinology Letters
• Review of studies2025
  Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties

  A review by an outside group of 25 years of Epitalon research. It found anti-ageing and hormone effects in lab, animal and computer studies. It said it is not clear these are the only ways Epitalon works. It also said the peptide itself is still poorly described.

  Independent narrative review of 25 years of Epitalon research. Notes geroprotective and neuroendocrine effects across in vitro, in vivo and in silico work, that it is uncertain whether the described mechanisms are the only ones, and that physicochemical and structural characterization of the peptide remains limited.

  PMID 40141333 International Journal of Molecular Sciences (Medical University of Warsaw)
• Review of studies2015
  Identification of the small research tetrapeptide Epitalon in two illegal pharmaceutical preparations

  A national public health lab in Belgium tested two illegal products. Both contained Epitalon. They were sold as treatments for cancer, ageing and an eye disease. This matters for what is really in grey-market vials.

  Laboratory analysis by a national public health institute confirming Epitalon as the constituent of two illegal preparations sold as treatments for cancer, aging and retinitis pigmentosa. Relevant to what is actually in gray-market vials.

  PMID 25535022 Drug Testing and Analysis (Belgian Scientific Institute of Public Health)
• Review of studies2026
  July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee

  The official FDA meeting record. On July 24, 2026, an FDA panel discussed Epitalon for the compounding list, for insomnia. The FDA's own scientists advised against it. The panel voted 7 to 4, with 1 not voting, to recommend it.

  Official FDA meeting record: Epitalon (free base and acetate) was discussed on July 24, 2026 for possible inclusion on the 503A bulk drug substances list, nominated for insomnia. FDA's own reviewers recommended against inclusion; the committee voted 7 to 4 with 1 abstention to recommend it.

  Source U.S. Food and Drug Administration
• Animal study2003
  Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice

  In mice. 54 mice per group got Epitalon 5 days a month from 3 months old. Average lifespan did not change. The longest-lived mice lived 12.3% longer. The last 10% of survivors lived 13.3% longer. Leukemia was 6 times less common.

  54 mice per group, 1 microgram per mouse on 5 consecutive days each month from age 3 months: no change in mean life span, but maximum life span rose 12.3%, the life span of the last 10% of survivors rose 13.3%, chromosome aberrations fell 17.1% and leukemia was inhibited 6-fold.

  PMID 14501183 Biogerontology
• Lab (cells in a dish)2003
  Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

  In a dish. In human fetal skin cells with no telomerase, Epitalon switched telomerase on and made telomeres longer. This is the result Epitalon is known for. It came from the group that made it.

  In telomerase-negative human fetal fibroblasts, Epithalon induced expression of the telomerase catalytic subunit, enzymatic activity and telomere elongation. This is the result the compound is known for; it was reported by the originating group.

  PMID 12937682 Bulletin of Experimental Biology and Medicine
• Lab (cells in a dish)2004
  Peptide promotes overcoming of the division limit in human somatic cell

  In a dish. Human fetal lung cells that stopped dividing at round 34 kept going to round 44 with Epitalon. Their telomeres grew back toward their early length. Same group as the 2003 paper.

  Human fetal lung fibroblasts that stopped dividing at passage 34 continued to passage 44 after Epithalon was added, with telomeres re-elongated toward early-passage length. Same group as the 2003 telomerase paper.

  PMID 15455129 Bulletin of Experimental Biology and Medicine
• Lab (cells in a dish)2025
  Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

  In a dish. The first time a lab with no link to the original group found the same direction of effect. Normal human cells grew longer telomeres, more so at higher doses. Cancer cells mostly used a different route. A November 2025 correction replaced three figures without changing the conclusions.

  The first replication of the direction of the telomere effect by a group unconnected to the originators: dose-dependent telomere lengthening in normal human epithelial and fibroblast cells through hTERT and telomerase, with alternative lengthening of telomeres seen mainly in cancer lines. A November 2025 correction notice (PMID 41240216) replaced Figures 1 to 3 without changing the conclusions.

  PMID 40908429 Biogerontology (Brunel University London)